Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: The goal of this study was to determine if memory would be improved by donepezil as compared to placebo in a multicenter, double-blind, randomized clinical trial (RCT). METHODS: Donepezil 10 mg daily was compared to placebo to treat memory impairment. Eligibility criteria included the following: age 18-59 years, clinically definite multiple sclerosis (MS), and performance ≤ ½ SD below published norms on the Rey Auditory Verbal Learning Test (RAVLT). Neuropsychological assessments were performed at baseline and 24 weeks. Primary outcomes were change on the Selective Reminding Test (SRT) of verbal memory and the participant's impression of memory change. Secondary outcomes included changes on other neuropsychological tests and the evaluating clinician's impression of memory change. RESULTS: A total of 120 participants were enrolled and randomized to either donepezil or placebo. No significant treatment effects were found between groups on either primary outcome of memory or any secondary cognitive outcomes. A trend was noted for the clinician's impression of memory change in favor of donepezil (37.7%) vs placebo (23.7%) (p = 0.097). No serious or unanticipated adverse events attributed to study medication developed. CONCLUSIONS: Donepezil did not improve memory as compared to placebo on either of the primary outcomes in this study. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence which does not support the hypothesis that 10 mg of donepezil daily for 24 weeks is superior to placebo in improving cognition as measured by the SRT in people with MS whose baseline RAVLT score was 0.5 SD or more below average.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Delis-Kaplan Executive Function System
Delis, D. C., Kaplan, E., & Kramer, J. H. (2012) · PsycTESTS Dataset · doi:10.1037/t15082-000 · Cited by 2,683
Confidence intervals for the number needed to treat.
Altman, D. G. (1998) · BMJ · doi:10.1136/bmj.317.7168.1309 · Cited by 938
Cognitive dysfunction in multiple sclerosis.: II. Impact on employment and social functioning
Rao, S. M., Leo, G. J., Ellington, L., Nauertz, T., Bernardin, L., & Unverzagt, F. (1991) · Neurology · doi:10.1212/wnl.41.5.692 · Cited by 890
Black, S., Román, G. C., Geldmacher, D. S., Salloway, S., Hecker, J., Burns, A., Perdomo, C., Kumar, D., & Pratt, R. (2003) · Stroke · doi:10.1161/01.str.0000091396.95360.e1 · Cited by 386 · cited 1×
“Anticonvulsant medication 14 (24) 12 (20)”
Cognitive and sedative effects of benzodiazepine use
Buffett-Jerrott, S., & Stewart, S. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023396654 · Cited by 312 · cited 1×
“Anticholinergic medications b 10 (17) 14 (23)”
Cited by
Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues
Benedict, R. H. B., Amato, M. P., DeLuca, J., & Geurts, J. J. G. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30277-5 · Cited by 764
Self-citationCognitive Dysfunction in Multiple Sclerosis
Guimarães, J., & Sá, M. J. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00074 · Cited by 427
Recommendations for cognitive screening and management in multiple sclerosis care
Kalb, R., Beier, M., Benedict, R. H., Charvet, L., Costello, K., Feinstein, A., Gingold, J., Goverover, Y., Halper, J., Harris, C., et al. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518803785 · Cited by 407
Self-citationWalczak-Nowicka, Ł. J., & Herbet, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179290 · Cited by 335
Treatment of progressive multiple sclerosis: what works, what does not, and what is needed
Feinstein, A., Freeman, J., & Lo, A. C. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70231-5 · Cited by 281
Metadata
- Authors
- Krupp, L. B., Christodoulou, C., Melville, P., Scherl, W. F., Pai, L.-Y., Muenz, L. R., He, D., Benedict, R. H. B., Goodman, A., Rizvi, S., Schwid, S. R., Weinstock-Guttman, B., Westervelt, H. J., & Wishart, H.
- Venue
- Neurology
- Published
- 2011-04-26
- Volume
- 76
- Issue
- 17
- Pages
- 1500-1507
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W4242280770
- Cited by
- 115
- References
- 5
- FWCI
- 8.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. https://app.cochat.ai/papers/10.1212/wnl.0b013e318218107a
- The paper
- Krupp, L. B., Christodoulou, C., Melville, P., Scherl, W. F., Pai, L.-Y., Muenz, L. R., He, D., Benedict, R. H. B., Goodman, A., Rizvi, S., Schwid, S. R., Weinstock-Guttman, B., Westervelt, H. J., & Wishart, H. (2011). Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology. https://doi.org/10.1212/wnl.0b013e318218107a
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.